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radiotherapy, however, imaging findings on anatomical contrast-enhanced MRI can be
unpredictable, highly variable, and are often difficult to interpret regarding treatment
response and outcome. This review aims at summarizing the imaging challenges
related to TT and ICI monotherapy as well as combined with radiotherapy in patients
with brain metastases, and to give an overview on advanced imaging techniques which
potentially overcome some of these imaging challenges. Currently, major evidence
suggests that imaging parameters especially derived from amino acid PET, perfusion-
/diffusion-weighted MRI, or MR spectroscopy may provide valuable additional
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Dear Professor Aldape, 
 
we would like to re-submit the revised manuscript entitled “Imaging 
challenges of immunotherapy and targeted therapy in patients 
with brain metastases: Response, Progression, and 
Pseudoprogression“ for publication as a review article in “Neuro-
Oncology”. 
 
We are grateful for the helpful comments of all reviewers and have 
studied their remarks carefully. The revision covers all of their 
suggestions and questions. In detail, we would like to respond to the 
reviewers' recommendations as indicated in the reply letter (changes 
in the manuscript are highlighted in red).  
 
We hope that the manuscript in the present form is now acceptable for 
publication in “Neuro-Oncology”. The manuscript or any part of it has 
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Cover Letter
REVIEWER #1:  
In this review article, the authors surveyed existing literature on imaging evaluation of 
BM patients treated with ICI or TT and attempted to answer some key questions to 
show how different imaging modalities may help in various situations including 
assessment of pseudoprogression and treatment response.   The organization of the 
article is good.  The shortcoming of the article, unfortunately, is the current lack of 
sufficient publications for many of the questions this article tries to address, and some 
topics the evidence is very minimal that I find it difficult to accept some of the 
conclusions made by the authors. Please see the following specific comments:  
 
COMMENT: The first part of article related to overview of ICI/TT and highlights of 
current challenges provides a good summary for the background.  The discussions 
related to pseudoprogression in glioblastoma undergoing standard treatment and 
iRANO seem out of place as the article is focusing on BM.  It can be confusing as the 
timing and incidences are different between these tumor types in the earlier 
paragraphs and the discussion of early pseudoprogression in SRS with ICI is 
discussed much later.  Perhaps the timing of the latter case more relevant for criteria 
similar to iRANO.    
REPLY: We agree with the reviewer’s opinion. The discussion related to 
pseudoprogression in glioblastoma undergoing standard treatment and iRANO has 
now been removed. 
 
COMMENT: The appearance of new lesion as a form of PSP should include 
references supporting this including timing for when this typically happens.  
REPLY: This has now been added to the corresponding section. 
  
COMMENT: Most of the discussion on imaging evaluation is based on SRS and very 
few articles are available for evaluation of ICI/TT treated BM patients using these 
advanced imaging techniques.  The roles of these methods in radiotherapy alone still 
need to be validated, and it might be premature to extrapolate such data to assess 
patients treated with ICI/TT which might manifest different treatment changes on 
imaging. 
REPLY: We agree with the reviewer’s opinion. This important aspect has now been 
added to the “Summary and Outlook” section. 
 
COMMENT: Since there are only a few articles focusing on added value of advanced 
imaging to assess ICI/TT patients, a more detailed discussion of the results should be 
included (including how many patients were evaluated and study method). For 
example, improved treatment response by FLT/FET PET compared to MRI should be 
discussed in more detail on how this was demonstrated in the references provided.   




REVIEWER #2:  
Well written review of immunotherapy challenges in the brain. Specific points below. 
 
COMMENT: Page 9 "As described by Wolchok...": Although the Wolchok paper and 
irRC are entirely relevant to the current review, and I agree with the authors' implicit 
application of the 4 patterns of response described for the systemic disease as 
Response to Reviewers
applicable to the brain, the authors should point out that the paper only discusses 
systemic metastases with no mention of the brain at all. 
REPLY: We completely agree with the reviewer’s opinion. This has now been stated 
more clearly in the corresponding section. 
 
COMMENT: Page 11 Hyperprogression: As the authors indicate, growth rate 
calculations are not standard for most patients. Do they have any suggestions on how 
this might be implemented?  
REPLY: We agree that the evaluation of the extracranial tumor growth rate before and 
after ICI initiation is not well defined. As stated in the manuscript, reports on 
hyperprogression after initiation of ICI monotherapy in patients with brain metastases 
remain scarce. Thus, it is still not yet clear whether hyperprogression may really occur 
in the CNS. This has now been stated more clearly in the corresponding section. 
Before a standardization of growth rate kinetics for the detection of CNS 
hyperprogression following ICI therapy should be established, more data on that 
(possible) phenomenon should be obtained.  
 
COMMENT: Page 15 PET: might be worthwhile to state that in the US, only FDG is 
FDA approved and all other radiotracers are typically only available as part of a clinical 
trial.  
REPLY: This has now been mentioned in the PET section. 
 
COMMENT: Page 20: For MRS, should also mention that successful MRS typically 
requires lesions at least 2cm3 in size, which is considerably larger than the other 
advanced imaging techniques. This might also be an opportunity to mention the other 
size limitations, which are typically about 8mm for PET and 5mm for 
perfusion/diffusion.  
REPLY: Lesion size limitations / requirements of all three imaging modalities have now 
been added to the corresponding sections. 
 
COMMENT: Page 22 Summary: Adding a suggested workup strategy might also be 
helpful. While this may vary considerably depending on local expertise and 
preferences, some techniques may be better for different lesion sizes as in the Page 
20 point.  
REPLY: A couple of recommendations have now been added to the Summary section. 
 
 
REVIEWER #3:  
COMMENT: Galldiks et al provide a timely, well-written and comprehensive update on 
challenges associated with response assessment with imaging modalities for brain 
metastases patients undergoing therapy with immune and biologic based therapies.  
Most of the manuscripts focused on this topic, align with the evaluation of glioblastoma 
patients; thus, the focus of this article on brain metastases provides a key update for 
an under-represented area of neuro-oncology. Nonetheless, growing therapeutic 
research is focusing on CNS metastases patients; thus, the article is much needed.  
 
Overall the authors have reviewed available data in a comprehensive manner. There 
are clear areas where sufficient data is lacking and these are candidly discussed in the 
article; thus, the article also highlights key areas where additional research is needed. 
 
The manuscript will benefit from a thorough editorial review as there are a few 
typographical/grammatical errors. Otherwise, the authors have provided a solid update 
for a needed area of focus in our field. 
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The advent of immunotherapy using immune checkpoint inhibitors (ICI) and targeted 
therapy (TT) has dramatically improved the prognosis of various cancer types. 
Following ICI therapy or TT, either alone (especially ICI) or in combination with 
radiotherapy, however, imaging findings on anatomical contrast-enhanced MRI can be 
unpredictable, highly variable, and are often difficult to interpret regarding treatment 
response and outcome. This review aims at summarizing the imaging challenges 
related to TT and ICI monotherapy as well as combined with radiotherapy in patients 
with brain metastases, and to give an overview on advanced imaging techniques which 
potentially overcome some of these imaging challenges. Currently, major evidence 
suggests that imaging parameters especially derived from amino acid PET, perfusion-
/diffusion-weighted MRI, or MR spectroscopy may provide valuable additional 
information for the differentiation of treatment-induced changes from brain metastases 
recurrence and the evaluation of treatment response. 
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The advent of immunotherapy using immune checkpoint inhibitors (ICI) and targeted 
therapy (TT) has dramatically improved the prognosis of cancer, especially in patients 
with melanoma, lung cancer, or breast cancer. Although initially tested only in patients 
with extracranial cancer manifestations, recent trials have demonstrated that patients 
with brain metastases (BM) may also benefit from these agents alone or in combination 
with other treatment options such as radiotherapy.  
 
Immunotherapy rests on the premise that tumors can be recognized as foreign rather 
than self, and that they thereby can be targeted by the activated immune system. 
Antibodies that block regulatory checkpoints of the immune system can facilitate an 
immune response that leads to inhibition of tumor growth or regression. In particular, 
the blockade of immune checkpoints such as the cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) or programmed cell death receptor-1 (PD-1) axis, has resulted in a 
significant improvement of prognosis and overall survival 1,2. Furthermore, the 
combination of ICIs, i.e., nivolumab with ipilimumab, can generate complete or partial 
response of selected BM in an even greater percentage of patients, especially in 
melanoma 3,4. Studies on the combination of ICIs with radiotherapy in patients with BM 
suggest that this approach is a valuable option that may offer improved survival over 
ICI therapy alone 5. 
 
In addition to ICI, TT using small molecules has demonstrated activity against BM 6-8. 
The presence of predictive genetic alterations such as EGFR mutation, ALK or ROS1 
translocation, HER2 overexpression, or BRAF V600E mutation is considered as an 
essential prerequisite for a response to TT 9. Similar to ICI, the combination of TT with 
radiotherapy also appears to be effective in patients with BM 10,11, although substantial 
N-O-D-19-00526R1 
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side effects may occur following TT concurrent to radiotherapy, especially when BRAF 
inhibitors are used 12.  
 
Following TT or ICI therapy, either alone (especially ICI) or in combination with 
radiotherapy, imaging findings on anatomical contrast-enhanced MRI can be 
unpredictable, highly variable, and the interpretation concerning the differentiation of 
treatment response from tumor progression is often challenging. For example, 
pseudoprogression is one of the most important critical clinical and imaging 
challenges. It refers primarily to MRI findings that are mimicking progressive tumor, 
which, however, are actually due to other causes, particularly, inflammation related to 
(ICI) therapy. If pseudoprogression is not correctly identified, the consequences for 
patients and clinicians may be substantial, e.g., premature discontinuation of an 
effective treatment with a negative impact on patient outcome may ensue. Conversely, 
trial results for recurrent disease may be compromised if patients with 
pseudoprogression are entered because this will result in overestimating the activity of 
the experimental intervention explored. Although the immunotherapy Response 
Assessment in Neuro-Oncology (iRANO) Working Group recently recommended 
standard MRI and clinical criteria for addressing the clinical problem of 
pseudoprogression following immunotherapy 13, to date the need for the acquisition of 
additional diagnostic information to overcome the problem of differentiating 
pseudoprogression from tumor progression remains of foremost importance.  
Furthermore, other imaging challenges (e.g., the assessment of response to TT and 
ICI therapy) are not specifically incorporated into the iRANO criteria. 
 
We here aim at summarizing clinically relevant imaging challenges related to TT and 
ICI monotherapy as well as TT or ICI therapy plus radiotherapy in patients with BM, 
N-O-D-19-00526R1 
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and at providing an overview on advanced imaging techniques that may help to 
overcome these challenges. 
 
SEARCH STRATEGY, SELECTION CRITERIA AND LEVELS OF VALIDATION  
A PubMed search of the published literature with the combination of the search terms 
“brain metastasis / metastases”, “MRI”, “MR”, advanced MRI”, “perfusion MRI”, “PWI”, 
diffusion MRI”, “DWI”, “ADC”, “spectroscopy”, “MRS”, “PET”, “positron”, “FDG”, “amino 
acid”, “methionine”, “FET”, “FDOPA”, “FLT”, “radiotherapy”, “WBRT”, “radiosurgery”, 
“gamma knife”, “radiation-induced changes / radiation injury”, “radionecrosis”, 
“radiation necrosis”, “pseudoprogression”, “progression”, “delayed / mixed response”, 
“treatment monitoring”, “assessment of treatment response”, “hyperprogression”, 
“abscopal effect”, “immunotherapy”, “ipilimumab”, “nivolumab”, “pembrolizumab”, 
“targeted therapy”, “EGFR”, “BRAF”, “HER2”, and “ALK” before and inclusive of 
Februar 2019 was performed. Additionally, articles identified through searches of the 
authors’ own files were included in the search. Only papers constituting levels 1-3 
evidence according to the Oxford Centre for Evidence-based Medicine (The Oxford 
2011 Levels of Evidence) were considered. In brief, a randomized controlled trial fulfills 
the criteria for Oxford level 1, a prospective cohort study corresponds to level 2, and a 









OVERVIEW ON IMAGING CHALLENGES FOLLOWING ICI AND TT IN PATIENTS 
WITH BM 
Pseudoprogression 
In patients undergoing immunotherapy using ICIs, intratumoral infiltrates including 
cytotoxic T cells (CD8+) may lead to pseudoprogressive MR imaging findings. 
Histopathology typically shows inflammatory cells 14, but not mitotically active tumor 
cells. Conversely, after ICI initiation progressive imaging changes might represent an 
initial true tumor progression that ultimately becomes controlled by a delayed immune 
response, subsequently leading to a decrease of tumor burden. Furthermore, a 
transient appearance of new contrast-enhancing lesions on MRI at either local or even 
distant sites might occur in patients with BM receiving ICIs. These findings suggest 
that new contrast-enhancing lesions might represent immune responses directed 
against infiltrative brain tumor cells. 
 
In extracranial solid tumors, the frequency of ICI-related pseudoprogression seems to 
be highest in melanoma treated with anti-CTLA-4 antibodies (range of 5-10% in the 
majority of studies) 15-17, but is lower in other solid tumors such as lung cancer treated 
with anti-PD-1/-PD-L1 antibodies (approximately 5%) 18,19. In contrast, data on the 
percentage of cases with pseudoprogression in patients with BM related to ICI 
monotherapy or ICI combination therapy are few 14,20-22. In a recent study in patients 
with BM from non-small cell lung cancer (NSCLC) treated with ICIs alone (n=1,025), 
the rate of pseudoprogression was only 0.8% 23, suggesting that this phenomenon is 
scarce in BM resulting from NSCLC or even misdiagnosed.  
 
The timing of pseudoprogressive changes in BM patients treated with ICIs has not 
been fully explored, but based on preliminary evidence this phenomenon may occur 
N-O-D-19-00526R1 
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early within the first weeks after initiation (range, 1.5 - 18 weeks) 14,20,21,24, but not later 
than 6 months. 
 
Regarding the occurrence of pseudoprogression in patients with BM related to TT 
monotherapy, data also remain scarce. In a NSCLC patient with ALK translocation, 
progressive MRI findings occurred after 12 months of alectinib treatment. Interestingly, 
histopathology was considered consistent with radiation necrosis although 
radiotherapy had been performed 7 years before the start of alectinib 25. 
 
Assessment of Treatment Response 
In patients with extracranial tumors treated with immunotherapy, Wolchok and 
colleagues described that basically four different patterns of response may occur: (i) 
rapid regression of baseline lesions without new lesions; (ii) durable stable disease (in 
some patients followed by a slow, steady decline in total tumor burden); (iii) an initial 
increase in tumor burden followed by (delayed) tumor regression; and (iv) the 
appearance of new lesions followed by a decrease in overall tumor burden 15. As stated 
above, the initial increase in tumor size or number of lesions in the latter two patterns 
does not always reflect actual disease progression, but may be related to 
pseudoprogression due to the influx of inflammatory cells. This important issue is also 
considered in frequently used immune-related response criteria, i.e., irRC 15, irRECIST 
26, and iRECIST 27. 
 
To rule out pseudoprogression following treatment for intracranial neoplasms, the 
iRANO criteria stipulate that within 6 months of initiating ICI therapy, early increases in 
lesion size and/or the development of new lesions do not define progressive disease 
unless further progressive changes are confirmed upon follow-up MR imaging, 
N-O-D-19-00526R1 
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provided that patients do not have clinical deterioration 13. After worsening of the first 
MR study after ICI therapy initiation, the iRANO criteria recommend a 3-months 
window for confirmation of progression 13. Besides, progressive imaging changes more 
than 6 months after immunotherapy initiation are more likely reflect an actual tumor 
progression 13,28,29. 
 
Thus, the early assessment of treatment response to ICI therapy may be thereby 
complicated by pseudoprogression. Furthermore, clinical evaluation of immunotherapy 
is also hampered by the absence of response criteria that can comprehensively 
describe all patterns of antitumor activity associated with such agents. In addition to 
the above stated four response patterns, lesions may also show “mixed” responses, 
consisting of regression in some lesions while others remained stable, progress, or 




In extracranial tumors, it has been observed that a subset of patients might experience 
a paradoxical acceleration of tumor growth kinetics after initiation of ICI therapy using 
anti-PD-1/-PD-L1 antibodies, which may lead to a considerably reduced overall 
survival. This phenomenon has been termed hyperprogression or hyperprogressive 
disease 32-34. The reported frequency for hyperprogression is in the range of 6-29% 
and varied considerably across different solid tumor types 32. The highest rates of 
hyperprogression have been observed in patients with head and neck squamous cell 




In clinical practice, the differentiation of hyperprogression from progressive tumors with 
a naturally aggressive phenotype remains a major challenge. To date, most of the 
current immune-related response criteria aim at identifying pseudoprogression but not 
hyperprogression. To recognize hyperprogression, it is important to integrate 
pretreatment tumor kinetics (tumor growth rate) by estimating the tumor size increase 
two- or three-dimensionally over time between two imaging studies. Subsequently, 
tumor growth rates can be used to compare the growth rate before and after initiating 
ICI. In several studies, at least a 2-fold increase of tumor growth on-treatment versus 
before ICI therapy has been considered as defining hyperprogressive disease 34,35. 
 
In patients with BM, reports on hyperprogression after initiation of ICI monotherapy 
remain scarce, and it is therefore still not yet clear whether hyperprogression may 
really occur in the CNS following ICI therapy. Kaito and co-workers reported a series 
of NSCLC patients (n=32) with a poor performance status or BM with severe 
exacerbations or manifestations of the primary disease related to nivolumab 37. The 
treatment was discontinued in 8 patients with BM due to severe exacerbation of 
neurologic symptoms (e.g., headache, gait disorder, disturbance of consciousness) 
indicating that hyperprogression may also occur in BM. However, BM growth rates 
before and after initiating ICI were not provided. 
 
Further Unsolved Imaging Challenges  
Several phase II and III trials in patients with BM have suggested that response to ICIs 
or TT on contrast-enhanced MRI based on frequently used response criteria 15,26,27,38,39 
is associated with considerably prolonged survival 3,4,40. However, there is an unmet 
need for the prediction of treatment response, e.g., by the evaluation of the tumor 
mutational burden 41 and molecular markers or non-invasively by using neuroimaging 
N-O-D-19-00526R1 
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biomarkers, ideally before the initiation of TT or ICI therapy. This is also of high clinical 
relevance, as these agents may cause severe side effects (i.e., CTCAE grade 3 and 
4) especially in patients with BM. 
 
ROLE OF RADIOTHERAPY IN COMBINATION WITH CI OR TT  
Synergistic effects of radiotherapy combined with ICI or TT 
Besides response, the therapeutic efficacy of any radiotherapy technique is usually 
determined in terms of the achieved local control rate of the irradiated lesion as well 
as the distant intracranial failure rate. Nowadays, radiosurgery is the dominant type of 
primary radiotherapy for patients with a limited number of small to middle-sized BM 42. 
Radiosurgery has high local efficacy, but does not target microscopic lesions distant 
to the lesions detected by brain imaging, and therefore the rate of distant BM in the 
further course of disease is usually high 43-46.  
 
The combination of radiosurgery with immunotherapy or TT may have synergistic 
effects on both irradiated and non-irradiated, distant regions. Within the target volume, 
the release of tumor cell antigens due to post-irradiation mitotic cell death may 
stimulate a cytotoxic immune response directed to the remaining tumor cells 47, leading 
to increased local response rates. Moreover, activated immune cells may also attack 
microscopic tumor cell clusters distant from the irradiated region, leading to a so-called 
abscopal effect 48 and a potential protection from the occurrence of distant BM. Figure 
1 shows neuropathological findings consistent with a distinct immune response most 
probably related to radiation therapy combined with targeted therapy. 
 
Several predominantly retrospective studies have addressed the effects combined 
therapy, i.e., radiosurgery and ICI or TT, compared to radiosurgery alone. Further 
N-O-D-19-00526R1 
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studies have focused on the optimal timing of systemic TT or ICI therapy relative to the 
time point of radiosurgery (Table 1). Studies of BM patients secondary to melanoma 
comparing radiosurgery and ICI or TT with radiosurgery alone suggest that combined 
therapies have the potential to increase response and local control rates compared to 
radiosurgery alone and can prevent distant BM at least to some extent 49-53. 
Additionally, the synergistic effects observed in patients with melanoma BM have also 
been observed in patients with BM from breast cancer 54-56. However, one study of 
patients with BM secondary to NSCLC did not find any synergistic effects of anti-PD1 
therapies in combination with radiosurgery 57.  
 
Regarding the optimal timing of systemic ICI therapy or TT and radiosurgery in 
melanoma patients with BM eligible for both approaches, the majority of these studies 
suggest that a faster and more pronounced or a more durable local response rate as 
well as a reduced distant intracranial failure rate were associated with a time interval 
of less than 4 weeks between initiation of systemic therapy and radiosurgery 58-65. 
However, randomized trials are needed to clarify whether radiosurgery should be 
applicated upfront or delayed at progression. 
 
Does ICI therapy or TT increase the rate of radiation necrosis after radiosurgery 
of brain metastases? 
After radiosurgery, approximately 30% of the lesions increase in size and change their 
pattern of contrast enhancement with a peak at 12-18 months after irradiation 66. Focal 
radiation necrosis is the most important type of late toxicity after radiosurgery. 
Histologically, radiation necrosis is characterized by a central area of necrosis 
surrounded by regions of vascular hyalinization, vasculitis, demyelination, macrophage 
and T-cell infiltration, and reactive astrocytosis 67,68. As these tissue changes are 
N-O-D-19-00526R1 
 14 
clearly involve immunogenic reactions, an interference with immuno-modulatory 
therapy can be expected. In clinical routine, treatment-related changes on MRI are 
frequently used as surrogate marker for radiation necrosis. Usually, the diagnosis is 
based upon serial MR images, although the diagnostic criteria may differ between 
institutions.  
 
Table 1 shows the rate of radiation necrosis in BM patients treated with radiosurgery 
alone in comparison to BM patients treated with radiosurgery combined with TT or ICI 
therapy. These selected studies (2016-2019; Table 1) suggest that an increased risk 
for radiation necrosis cannot be excluded when radiosurgery is applied in combination 
with ICI therapy while the combination of radiosurgery with TT seems to be less prone 
to radiation necrosis. 
 
Pseudoprogression and Radiosurgery in Combination with ICI 
The occurrence of pseudoprogression after radiosurgery in combination with ICI 
therapy has so far not been well recognized. Compared to radiation necrosis, 
pseudoprogression may differ in terms of the time course of development (typically 
earlier) and the tissue reactions involved. A recent study observed that approximately 
20% of the treated BM showed a transient, reversible increase in size 3-6 months after 
combined treatment compared to 5% after radiosurgery alone 24. Rahman et al. 63 
reported that about 50% of melanoma patients concurrently treated with ipilimumab, 
pembrolizumab, or nivolumab and radiosurgery had an earlier tumor progression 
compared to those treated with ICI therapy with more time elapsed since radiosurgery. 
Despite these earlier tumor progressions, the concurrent patients had a better 
intracranial progression-free survival (30% vs. 12% at 12 months). The phenomenon 
of pseudoprogression has also been observed in melanoma BM patients treated with 
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PD-1 antagonists administered less than 6 weeks after radiosurgery 69. These findings 
warrant consideration during follow-up when interpreting conventional MRI.   
 
PET AND ADVANCED MRI AS NEUROIMAGING TOOLS TO OVERCOME 
CHALLENGES OF CONVENTIONAL MRI 
Currently, ICIs and TT are being investigated in clinical trials while already being used 
in clinical practice for patients with BM. While these therapies hold great promise, 
management of patients undergoing these treatments can be complicated due to brain 
imaging findings on standard MRI, e.g., immune-related pseudoprogression caused by 
ICI therapy or equivocal MRI findings related to radiation in combination with TT. Thus, 
ICIs and TT impose specific requirements on neuroimaging which are not met by 
anatomical MRI. Metabolic PET imaging and advanced MR techniques may provide 
helpful objective information to overcome these imaging challenges. An overview is 
presented in Table 2. 
 
PET 
Oncologic PET imaging using [18F]-2-fluoro-2-deoxy-D-glucose (FDG) has evolved 
over the last decades into the paramount clinical PET modality for cancer diagnostics 
70. Increased glucose metabolism as assessed by an increased FDG uptake is 
commonly seen in proliferating tumor cells due to an increased expression of glucose 
transporters and the enzyme hexokinase, which converts FDG to a phosphorylated 
product. However, the physiological high FDG uptake in the normal brain parenchyma 
hinders the delineation of brain tumors 71, and cerebral inflammatory processes may 




Radiolabeled amino acids are of particular interest for brain tumor imaging using PET 
because of their increased uptake in neoplastic tissue but low uptake in normal brain 
parenchyma, resulting in an improved tumor-to-brain contrast 72. A key feature of 
amino acid tracers is their ability to pass the intact blood-brain-barrier which allows the 
depiction of glioma tissue beyond contrast enhancement in MRI 72 and to differentiate 
tumor progression from non-specific, treatment-related changes, especially in patients 
with BM 73. Recently, the RANO group has analyzed the clinical value of amino acid 
PET in the diagnostic evaluation of brain tumors. It strongly recommended the use of 
this imaging technique in addition to conventional MRI especially for the delineation of 
brain tumor extent, treatment response assessment, evaluation of prognosis of newly 
diagnosed brain tumors, and the differentiation of treatment-related changes from 
tumor progression 71,73-76. Within the group of amino acid PET tracers, [11C]-methyl-L-
methionine (MET), 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA), and O-(2-
[18F]-fluoroethyl)-L-tyrosine (FET) are frequently used 72,77,78. In both gliomas and BM, 
increased uptake of MET, FET, and FDOPA is related to amino acid transporters of 
the L type (LAT; subtypes LAT1 and LAT2), which are overexpressed in tumor tissue 
79-82. Thus, the LAT transporter overexpression in BM makes intracranial metastases 
a compelling target for amino acid PET imaging 82. 
 
In patients with BM, a few PET imaging studies have used other tracers than FDG or 
radiolabeled amino acids. For example, the PET tracer 3´-deoxy-3´-[18F]-
fluorothymidine (FLT) is an analog to the nucleoside thymidine, and was developed to 
assess cellular proliferation by tracking the thymidine salvage pathway 83. The few data 
thus far available suggest that in patients with brain tumors including BM, this tracer 




Importantly, in the USA, only FDG is FDA-approved and all other radiotracers are 
typically only available as part of a clinical trial. 
 
Differentiation of Radiation-induced Changes from Brain Metastasis Recurrence  
FDG PET has been studied to differentiate radiation-induced changes from BM 
relapse. Interestingly, the diagnostic performance of FDG PET varied considerably 
(range of sensitivity, 40-95%; range of specificity, 50-100%) 85-90. Most probably, these 
results might be related to a low number of patients and by variations in methodology. 
 
In contrast, FDOPA PET and MET PET have consistently demonstrated higher 
sensitivity and specificity of approximately 80% in differentiating treatment effect from 
BM recurrence 91-94. Another study has reported a high accuracy for differentiating 
radiation-induced changes from BM relapse after radiosurgery using FDOPA PET, out-
performing perfusion MRI parameters 91% to 76% 95.  Similarly, static and dynamic 
FET PET parameters showed a high diagnostic performance with a sensitivity and 
specificity of 80-90% for the differentiation of radiation-induced changes from locally 
recurrent BM 96-98. An illustrative case is presented in Figure 2. Furthermore, the 
diagnostic performance of amino acid PET seems to be superior to both glucose PET 
and perfusion- and diffusion-weighted MR imaging 90,95.  
 
Recent literature highlights the value of radiomics and artificial intelligence in the field 
of Neuro-Oncology 99-101. Radiomics enables the high-throughput extraction of 
quantitative imaging features from MRI as well as PET 102,103. Using FET PET, it has 
been demonstrated that radiomic textural feature analysis helps distinguishing 
treatment-related changes from BM recurrence 104. For this important clinical question, 
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radiomics analysis using the combination of textural features obtained from FET PET 
and contrast-enhanced MRI achieved a high diagnostic specificity (> 90%) 105. 
 
As stated above, pseudoprogression may occur in patients with BM treated with 
(mono-)immunotherapy using checkpoint inhibitors such as antibodies to CTLA-4 (e.g., 
ipilimumab), PD-1 (e.g., pembrolizumab or nivolumab), or PD-L1 (e.g., atezolizumab). 
A small pilot study (n=5 patients) highlighted the potential of FET PET to identify 
pseudoprogression in patients with BM secondary to melanoma treated with the ICI 
ipilimumab 20. In that study, FET PET imaging findings were correlated with the 
patients’ clinical course after ICI therapy initiation. In the case of pseudoprogression, 
FET PET showed in contrast to the progressive MRI only minimal or even no uptake 
and the outcome was favorable (> 6 months). 
 
Assessment of Treatment Response 
In patients (n=5) with melanoma BM (n=22) treated with TT or ICI therapy, a small 
prospective study found in a subset of patients that metabolic responders may show a 
proliferative reduction on FLT PET despite unchanged findings on standard MRI 106. 
Furthermore, FLT PET responders had a survival of more than 12 months after therapy 
initiation. The pilot data suggest that FLT PET also has the potential to detect a 
reduction of proliferative tumor activity despite apparent morphologic progression on 
conventional MRI (i.e., pseudoprogression). 
 
While the value of amino acid PET for the assessment of treatment response in 
gliomas is well established 107, studies on BM are still remain scarce. Single case 
reports suggest that amino acid PET has the potential to add valuable information to 
standard MRI for the assessment of treatment response. Similar to FLT PET, a 
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reduction of metabolic activity in BM patients secondary to melanoma or NSCLC 
treated with TT could be identified by FET PET, whereas findings on standard MRI 
remained unchanged 73,108. 
 
ADVANCED MRI 
While conventional MRI is exceptional in providing detailed anatomical information of 
both the central nervous system and brain tumors, advanced MRI methods offer the 
ability to yield valuable information concerning the tumor biology, especially at the 
functional, physiologic and molecular level. Commonly used advanced MR techniques 
include perfusion-weighted imaging (PWI), MR spectroscopy (MRS), and diffusion-
weighted imaging (DWI). Due to a better scanner resolution, smaller lesions 
(approximately 5 mm in diameter) can be better evaluated by MRI techniques than by 
PET (optimal lesion diameter, 10 mm or more). 
 
Differentiation of Radiation-induced Changes from Brain Metastasis Recurrence 
 
A recent meta-analysis by Chuang and colleagues 109 examined the value of various 
imaging parameters derived from PWI and MRS for the differentiation of recurrent 
tumor from radiation-induced necrosis in brain tumors patients. Of 397 brain tumor 
patients encompassed by 13 studies, 95 patients suffered from BM, and the remaining 
patiens had gliomas. The main finding of that meta-analysis was that MR spectroscopy 
and MR perfusion might increase the accuracy of differentiating recurrent tumor from 
radiation-induced necrosis in patients with gliomas or BM. In particular, the relative 
cerebral blood volume (rCBV) derived from PWI as well as various MRS metabolite 
ratios in contrast-enhancing lesions was significantly different in BM recurrence 




Regarding the diagnostic performance of PWI, the available studies revealed a 
considerable variability of sensitivity and specificity (range of sensitivity, 56-100%; 
range of specificity, 68-100%) and rCBV thresholds (range, 1.52 - 2.14) 89,95,110-113. 
Although PWI separates radiation-induced changes from BM recurrence with a 
relatively good accuracy in individual studies, there is a significant variability in optimal 
reported thresholds and methodology indicate that further studies and standardization 
are warranted. 
 
For MRS, the specificity for the detection of BM recurrence seems to be high (100% 
across all studies), whereas the sensitivity is relatively low (range, 33-50%) 112,114. Of 
note, MRS studies evaluating this clinical question remain comparatively rare and may 
be limited by a small lesion size (i.e., < 2 cm3). 
 
Apparent diffusion coefficients (ADC) obtained from DWI seem to be inferior to amino 
acid PET using MET for distinguishing radiation-induced injury from BM recurrence 
(area under the curve obtained from receiver operating characteristic curve analyses, 
0.60 vs. 0.81) 90. Furthermore, in contrast to the rCBV, ADC values seem not to be of 
value for the detection of treatment-related changes after stereotactic radiotherapy of 
BM 115. 
 
A radiomics-based prediction model based on contrast-enhanced T1 and FLAIR 
images has been used for distinguishing actual tumor progression from radionecrosis 
after stereotactic radiosurgery for BM patients 116. After cross-validation of the model, 
the radiomics analysis revealed a sensitivity and specificity of 65% and 87%, 




Evaluation of Response to Radiotherapy 
For the evaluation of treatment response in patients with BM, a variety of parameters 
obtained from dynamic susceptibility contrast (DSC), dynamic contrast-enhanced 
(DCE), or arterial spin labeling (ASL) perfusion MRI have been evaluated, including 
predominantly the rCBV, the relative cerebral blood flow (rCBF), and Ktrans (which 
reflects the efflux rate of gadolinium contrast from blood plasma into the tissue). 
 
Taunk and co-workers evaluated pre- and post-treatment stereotactic radiosurgery 
effects in 41 NSCLC patients with 53 BM using DCE PWI 117. Already within the first 
12 weeks after radiosurgery, the PWI parameter Ktrans could be used to predict long-
term response (median follow-up, 11 months) in this group of patients to stereotactic 
radiosurgery. Similar findings regarding the parameter Ktrans have been observed in 
previous PWI studies 118,119. 
 
In 25 patients with 28 BM treated with radiosurgery, rCBF alterations after 6 weeks as 
assessed using DSC or ASL allowed the prediction of the treatment effect (median 
follow-up, 6 months) 120. Similarly, Essig et al. found that a decrease of the rCBV at the 
6-week follow-up helped to predict the treatment outcome with a sensitivity of more 
than 90%. In contrast, the pre-therapeutic rCBV was unable to help predict treatment 
outcome 121. 
 
In patients with BM predominantly ADC values obtained from DWI have also been 
evaluated for the evaluation of treatment response, i.e., especially the response to 
radiosurgery. A few studies have suggested that patients with treatment-responsive 
BM the ADC values increased during follow-up after radiosurgery 122-124. Conversely, 
Jakubovic and colleagues evaluated 42 patients with 70 BM and observed - in contrast 
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to the aforementioned studies - that especially lower ADC values already at one week 
and one month identified responders to radiosurgery 125. Regarding the prediction of 
tumor response, Lee found that initial (pretreatment) ADC values of 107 patients with 
144 BM were able to predict response to radiosurgery with a sensitivity and specificity 
of 86% and 73%, respectively 126. 
  
Additionally, more sophisticated imaging postprocessing techniques of DWI such as 
the calculation of the diffusion abnormality probability function or functional diffusion 
maps seem to provide a reliable prediction of BM response to radiotherapy 127,128. 
 
SUMMARY AND OUTLOOK 
Advanced MRI and PET techniques have the great potential to noninvasively 
investigate the molecular, cellular, and structural components of the tumor and its 
microenvironment. In the light of recent treatment options for patients with BM such as 
ICI and TT and their potential side effects as well as ensuing imaging challenges, it is 
of paramount interest to both visualize and quantify metabolic and (patho)physiological 
changes, especially inflammation, before and during treatment.  
 
Currently, significant evidence suggests that imaging parameters especially derived 
from amino acid PET, PWI, DWI, or MRS may provide valuable additional information 
for the differentiation of treatment-induced changes from BM recurrence and the 
evaluation of treatment response. The PET/RANO group has recently published 
various recommendations which imaging modality should be preferred 73: Amino acid 
PET may be more useful than advanced MRI, whereas FDG PET appears to be 
inferior. However, at present direct comparisons of advanced MRI versus PET are 
limited. When using PET for this indication, amino acid tracers should be preferred 
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because present studies consistently show high diagnostic accuracy. Nevertheless, 
only little data is currently available for evaluation of ICI/TT-treated BM patients using 
these advanced imaging techniques. 
 
It is tempting to speculate that a multimodal approach combining parameters derived 
from each of these advanced imaging techniques may improve the diagnostic 
performance. To further improve the diagnostic accuracy and to assess the resulting 
clinical impact, multicenter studies are warranted that also standardize imaging 
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Figure 1: Radiation necrosis and chronic inflammation in a patient with brain 
metastases of a BRAF-mutated malignant melanoma who had been treated with 
whole-brain radiation therapy and concurrently with dabrafenib plus trametinib. 
Twenty-four months later, the contrast-enhanced MRI suggests brain metastasis 
recurrence (left panel), whereas the FET PET shows only an insignificant uptake, 
consistent with treatment-related effects. Neuropathological findings obtained 
following stereotactic biopsy revealed besides signs of radiation necrosis a 
considerable infiltration of intra- and perivascular T-cells (right panel):  
A: Hyaline, eosinophilic necrosis with only single leukocytes and cell detritus. A 
necrotic vessel wall is hyalinized and thickened (arrowhead). H&E staining; original 
magnification x 200. 
B: Adjacent to necrosis, small fragments of vital brain parenchyma harbor activated 
microglial cells (arrowhead) and reactive astrocytes (asterisk). Two blood vessels are 
heavily infiltrated by lymphocytes (arrows). Tumor cells are absent (insert). H&E 
staining; original magnification x 500; insert: immunohistochemistry with monoclonal 
mouse anti-HMB45 (DCS) and slight counterstaining with hemalum; original 
magnification, x200. 
C: Adjacent to the inflamed blood vessels (arrows), foamy CD68+ macrophages are 
in the process of resorption of necrosis (block arrows). In the brain parenchyma, 
microglial cells (arrowheads) and astrocytes (insert, asterisks) are activated. 
Immunohistochemistry with monoclonal mouse anti-CD68 (DCS) and slight 
counterstaining with hemalum; original magnification, x200; insert: 
immunohistochemistry with monoclonal mouse anti-GFAP (BioGenex) and slight 
counterstaining with hemalum; original magnification, x500. 
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D: CD3+ T cells are the major population of intra- and perivascular infiltrates (arrow). 
Both, CD4+ (left insert) and CD8+ (right insert) T cells contribute to the infiltrates. 
Immunohistochemistry with monoclonal rabbit anti-CD3 (DCS) and slight 
counterstaining with hemalum; original magnification, x200; inserts: 
immunohistochemistry with monoclonal mouse anti-CD4 (left, BioGenex) and with 
monoclonal rabbit anti-CD8 (right, DCS), slight counterstaining with hemalum; original 
magnification, x400.  
 
Figure 2: Radiation necrosis in a patient with brain metastases secondary to a breast 
cancer (ductal carcinoma, HER-2 negative, estrogen and progesterone receptor-
positive) (left panel). Five months after external fractionated radiation therapy, 
contrast-enhanced MRI suggests BM relapse (middle panel). In contrast, FET PET 
shows no increased metabolic activity, indicating treatment-related changes. 
Neuropathological findings obtained following stereotactic biopsy were consistent with 
radiation necrosis (right panel):  
A: Epithelial, pleomorphic tumor with increased mitotic activity (arrowheads) in the 
brain parenchyma expressing cytokeratin (CK) 8 (insert) at initial diagnosis. H&E 
staining; original magnification x 200. Insert: immunohistochemistry with monoclonal 
mouse anti-CK8 (BioGenex, Fremont, CA, USA) and slight counterstaining with 
hemalum; original magnification, x100. 
B: Hyaline, eosinophilic necrosis with only single leukocytes. A necrotic vessel wall is 
hyalinized and thickened (insert). Adjacent vital brain parenchyma shows reactive 
alterations with activated microglial cells and reactive astrocytes. H&E staining; original 
magnification x 200; insert: H&E staining; original magnification, x500. 
C: Necrosis is infiltrated by foamy macrophages (arrows). In the brain parenchyma, 
microglial cells (arrowheads) and astrocytes (insert, asterisks) are activated. 
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Immunohistochemistry with monoclonal mouse anti-MHC class I antigen (DCS, 
Hamburg, Germany) and slight counterstaining with hemalum; original magnification x 
200; insert: immunohistochemistry with monoclonal mouse anti-GFAP (BioGenex) and 
slight counterstaining with hemalum; original magnification, x500. 
D: Epithelial tumor cells were absent from necrosis and vital brain parenchyma. 
Immunohistochemistry with monoclonal mouse anti-CK8 (BioGenex) and slight 
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The advent of immunotherapy using immune checkpoint inhibitors (ICI) and targeted 
therapy (TT) has dramatically improved the prognosis of various cancer types. 
Following ICI therapy or TT, either alone (especially ICI) or in combination with 
radiotherapy, however, imaging findings on anatomical contrast-enhanced MRI can be 
unpredictable, highly variable, and are often difficult to interpret regarding treatment 
response and outcome. This review aims at summarizing the imaging challenges 
related to TT and ICI monotherapy as well as combined with radiotherapy in patients 
with brain metastases, and to give an overview on advanced imaging techniques which 
potentially overcome some of these imaging challenges. Currently, major evidence 
suggests that imaging parameters especially derived from amino acid PET, perfusion-
/diffusion-weighted MRI, or MR spectroscopy may provide valuable additional 
information for the differentiation of treatment-induced changes from brain metastases 
recurrence and the evaluation of treatment response. 
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The advent of immunotherapy using immune checkpoint inhibitors (ICI) and targeted 
therapy (TT) has dramatically improved the prognosis of cancer, especially in patients 
with melanoma, lung cancer, or breast cancer. Although initially tested only in patients 
with extracranial cancer manifestations, recent trials have demonstrated that patients 
with brain metastases (BM) may also benefit from these agents alone or in combination 
with other treatment options such as radiotherapy.  
 
Immunotherapy rests on the premise that tumors can be recognized as foreign rather 
than self, and that they thereby can be targeted by the activated immune system. 
Antibodies that block regulatory checkpoints of the immune system can facilitate an 
immune response that leads to inhibition of tumor growth or regression. In particular, 
the blockade of immune checkpoints such as the cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) or programmed cell death receptor-1 (PD-1) axis, has resulted in a 
significant improvement of prognosis and overall survival 1,2. Furthermore, the 
combination of ICIs, i.e., nivolumab with ipilimumab, can generate complete or partial 
response of selected BM in an even greater percentage of patients, especially in 
melanoma 3,4. Studies on the combination of ICIs with radiotherapy in patients with BM 
suggest that this approach is a valuable option that may offer improved survival over 
ICI therapy alone 5. 
 
In addition to ICI, TT using small molecules has demonstrated activity against BM 6-8. 
The presence of predictive genetic alterations such as EGFR mutation, ALK or ROS1 
translocation, HER2 overexpression, or BRAF V600E mutation is considered as an 
essential prerequisite for a response to TT 9. Similar to ICI, the combination of TT with 
radiotherapy also appears to be effective in patients with BM 10,11, although substantial 
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side effects may occur following TT concurrent to radiotherapy, especially when BRAF 
inhibitors are used 12.  
 
Following TT or ICI therapy, either alone (especially ICI) or in combination with 
radiotherapy, imaging findings on anatomical contrast-enhanced MRI can be 
unpredictable, highly variable, and the interpretation concerning the differentiation of 
treatment response from tumor progression is often challenging. For example, 
pseudoprogression is one of the most important critical clinical and imaging 
challenges. It refers primarily to MRI findings that are mimicking progressive tumor, 
which, however, are actually due to other causes, particularly, inflammation related to 
(ICI) therapy. If pseudoprogression is not correctly identified, the consequences for 
patients and clinicians may be substantial, e.g., premature discontinuation of an 
effective treatment with a negative impact on patient outcome may ensue. Conversely, 
trial results for recurrent disease may be compromised if patients with 
pseudoprogression are entered because this will result in overestimating the activity of 
the experimental intervention explored. Although the immunotherapy Response 
Assessment in Neuro-Oncology (iRANO) Working Group recently recommended 
standard MRI and clinical criteria for addressing the clinical problem of 
pseudoprogression following immunotherapy 13, to date the need for the acquisition of 
additional diagnostic information to overcome the problem of differentiating 
pseudoprogression from tumor progression remains of foremost importance.  
Furthermore, other imaging challenges (e.g., the assessment of response to TT and 
ICI therapy) are not specifically incorporated into the iRANO criteria. 
 
We here aim at summarizing clinically relevant imaging challenges related to TT and 
ICI monotherapy as well as TT or ICI therapy plus radiotherapy in patients with BM, 
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and at providing an overview on advanced imaging techniques that may help to 
overcome these challenges. 
 
SEARCH STRATEGY, SELECTION CRITERIA AND LEVELS OF VALIDATION  
A PubMed search of the published literature with the combination of the search terms 
“brain metastasis / metastases”, “MRI”, “MR”, advanced MRI”, “perfusion MRI”, “PWI”, 
diffusion MRI”, “DWI”, “ADC”, “spectroscopy”, “MRS”, “PET”, “positron”, “FDG”, “amino 
acid”, “methionine”, “FET”, “FDOPA”, “FLT”, “radiotherapy”, “WBRT”, “radiosurgery”, 
“gamma knife”, “radiation-induced changes / radiation injury”, “radionecrosis”, 
“radiation necrosis”, “pseudoprogression”, “progression”, “delayed / mixed response”, 
“treatment monitoring”, “assessment of treatment response”, “hyperprogression”, 
“abscopal effect”, “immunotherapy”, “ipilimumab”, “nivolumab”, “pembrolizumab”, 
“targeted therapy”, “EGFR”, “BRAF”, “HER2”, and “ALK” before and inclusive of 
Februar 2019 was performed. Additionally, articles identified through searches of the 
authors’ own files were included in the search. Only papers constituting levels 1-3 
evidence according to the Oxford Centre for Evidence-based Medicine (The Oxford 
2011 Levels of Evidence) were considered. In brief, a randomized controlled trial fulfills 
the criteria for Oxford level 1, a prospective cohort study corresponds to level 2, and a 









OVERVIEW ON IMAGING CHALLENGES FOLLOWING ICI AND TT IN PATIENTS 
WITH BM 
Pseudoprogression 
In patients undergoing immunotherapy using ICIs, intratumoral infiltrates including 
cytotoxic T cells (CD8+) may lead to pseudoprogressive MR imaging findings. 
Histopathology typically shows inflammatory cells 14, but not mitotically active tumor 
cells. Conversely, after ICI initiation progressive imaging changes might represent an 
initial true tumor progression that ultimately becomes controlled by a delayed immune 
response, subsequently leading to a decrease of tumor burden. Furthermore, a 
transient appearance of new contrast-enhancing lesions on MRI at either local or even 
distant sites might occur in patients with BM receiving ICIs. These findings suggest 
that new contrast-enhancing lesions might represent immune responses directed 
against infiltrative brain tumor cells. 
 
In extracranial solid tumors, the frequency of ICI-related pseudoprogression seems to 
be highest in melanoma treated with anti-CTLA-4 antibodies (range of 5-10% in the 
majority of studies) 15-17, but is lower in other solid tumors such as lung cancer treated 
with anti-PD-1/-PD-L1 antibodies (approximately 5%) 18,19. In contrast, data on the 
percentage of cases with pseudoprogression in patients with BM related to ICI 
monotherapy or ICI combination therapy are few 14,20-22. In a recent study in patients 
with BM from non-small cell lung cancer (NSCLC) treated with ICIs alone (n=1,025), 
the rate of pseudoprogression was only 0.8% 23, suggesting that this phenomenon is 
scarce in BM resulting from NSCLC or even misdiagnosed.  
 
The timing of pseudoprogressive changes in BM patients treated with ICIs has not 
been fully explored, but based on preliminary evidence this phenomenon may occur 
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early within the first weeks after initiation (range, 1.5 - 18 weeks) 14,20,21,24, but not later 
than 6 months. 
 
Regarding the occurrence of pseudoprogression in patients with BM related to TT 
monotherapy, data also remain scarce. In a NSCLC patient with ALK translocation, 
progressive MRI findings occurred after 12 months of alectinib treatment. Interestingly, 
histopathology was considered consistent with radiation necrosis although 
radiotherapy had been performed 7 years before the start of alectinib 25. 
 
Assessment of Treatment Response 
In patients with extracranial tumors treated with immunotherapy, Wolchok and 
colleagues described that basically four different patterns of response may occur: (i) 
rapid regression of baseline lesions without new lesions; (ii) durable stable disease (in 
some patients followed by a slow, steady decline in total tumor burden); (iii) an initial 
increase in tumor burden followed by (delayed) tumor regression; and (iv) the 
appearance of new lesions followed by a decrease in overall tumor burden 15. As stated 
above, the initial increase in tumor size or number of lesions in the latter two patterns 
does not always reflect actual disease progression, but may be related to 
pseudoprogression due to the influx of inflammatory cells. This important issue is also 
considered in frequently used immune-related response criteria, i.e., irRC 15, irRECIST 
26, and iRECIST 27. 
 
To rule out pseudoprogression following treatment for intracranial neoplasms, the 
iRANO criteria stipulate that within 6 months of initiating ICI therapy, early increases in 
lesion size and/or the development of new lesions do not define progressive disease 
unless further progressive changes are confirmed upon follow-up MR imaging, 
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provided that patients do not have clinical deterioration 13. After worsening of the first 
MR study after ICI therapy initiation, the iRANO criteria recommend a 3-months 
window for confirmation of progression 13. Besides, progressive imaging changes more 
than 6 months after immunotherapy initiation are more likely reflect an actual tumor 
progression 13,28,29. 
 
Thus, the early assessment of treatment response to ICI therapy may be thereby 
complicated by pseudoprogression. Furthermore, clinical evaluation of immunotherapy 
is also hampered by the absence of response criteria that can comprehensively 
describe all patterns of antitumor activity associated with such agents. In addition to 
the above stated four response patterns, lesions may also show “mixed” responses, 
consisting of regression in some lesions while others remained stable, progress, or 




In extracranial tumors, it has been observed that a subset of patients might experience 
a paradoxical acceleration of tumor growth kinetics after initiation of ICI therapy using 
anti-PD-1/-PD-L1 antibodies, which may lead to a considerably reduced overall 
survival. This phenomenon has been termed hyperprogression or hyperprogressive 
disease 32-34. The reported frequency for hyperprogression is in the range of 6-29% 
and varied considerably across different solid tumor types 32. The highest rates of 
hyperprogression have been observed in patients with head and neck squamous cell 




In clinical practice, the differentiation of hyperprogression from progressive tumors with 
a naturally aggressive phenotype remains a major challenge. To date, most of the 
current immune-related response criteria aim at identifying pseudoprogression but not 
hyperprogression. To recognize hyperprogression, it is important to integrate 
pretreatment tumor kinetics (tumor growth rate) by estimating the tumor size increase 
two- or three-dimensionally over time between two imaging studies. Subsequently, 
tumor growth rates can be used to compare the growth rate before and after initiating 
ICI. In several studies, at least a 2-fold increase of tumor growth on-treatment versus 
before ICI therapy has been considered as defining hyperprogressive disease 34,35. 
 
In patients with BM, reports on hyperprogression after initiation of ICI monotherapy 
remain scarce, and it is therefore still not yet clear whether hyperprogression may 
really occur in the CNS following ICI therapy. Kaito and co-workers reported a series 
of NSCLC patients (n=32) with a poor performance status or BM with severe 
exacerbations or manifestations of the primary disease related to nivolumab 37. The 
treatment was discontinued in 8 patients with BM due to severe exacerbation of 
neurologic symptoms (e.g., headache, gait disorder, disturbance of consciousness) 
indicating that hyperprogression may also occur in BM. However, BM growth rates 
before and after initiating ICI were not provided. 
 
Further Unsolved Imaging Challenges  
Several phase II and III trials in patients with BM have suggested that response to ICIs 
or TT on contrast-enhanced MRI based on frequently used response criteria 15,26,27,38,39 
is associated with considerably prolonged survival 3,4,40. However, there is an unmet 
need for the prediction of treatment response, e.g., by the evaluation of the tumor 
mutational burden 41 and molecular markers or non-invasively by using neuroimaging 
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biomarkers, ideally before the initiation of TT or ICI therapy. This is also of high clinical 
relevance, as these agents may cause severe side effects (i.e., CTCAE grade 3 and 
4) especially in patients with BM. 
 
ROLE OF RADIOTHERAPY IN COMBINATION WITH CI OR TT  
Synergistic effects of radiotherapy combined with ICI or TT 
Besides response, the therapeutic efficacy of any radiotherapy technique is usually 
determined in terms of the achieved local control rate of the irradiated lesion as well 
as the distant intracranial failure rate. Nowadays, radiosurgery is the dominant type of 
primary radiotherapy for patients with a limited number of small to middle-sized BM 42. 
Radiosurgery has high local efficacy, but does not target microscopic lesions distant 
to the lesions detected by brain imaging, and therefore the rate of distant BM in the 
further course of disease is usually high 43-46.  
 
The combination of radiosurgery with immunotherapy or TT may have synergistic 
effects on both irradiated and non-irradiated, distant regions. Within the target volume, 
the release of tumor cell antigens due to post-irradiation mitotic cell death may 
stimulate a cytotoxic immune response directed to the remaining tumor cells 47, leading 
to increased local response rates. Moreover, activated immune cells may also attack 
microscopic tumor cell clusters distant from the irradiated region, leading to a so-called 
abscopal effect 48 and a potential protection from the occurrence of distant BM. Figure 
1 shows neuropathological findings consistent with a distinct immune response most 
probably related to radiation therapy combined with targeted therapy. 
 
Several predominantly retrospective studies have addressed the effects combined 
therapy, i.e., radiosurgery and ICI or TT, compared to radiosurgery alone. Further 
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studies have focused on the optimal timing of systemic TT or ICI therapy relative to the 
time point of radiosurgery (Table 1). Studies of BM patients secondary to melanoma 
comparing radiosurgery and ICI or TT with radiosurgery alone suggest that combined 
therapies have the potential to increase response and local control rates compared to 
radiosurgery alone and can prevent distant BM at least to some extent 49-53. 
Additionally, the synergistic effects observed in patients with melanoma BM have also 
been observed in patients with BM from breast cancer 54-56. However, one study of 
patients with BM secondary to NSCLC did not find any synergistic effects of anti-PD1 
therapies in combination with radiosurgery 57.  
 
Regarding the optimal timing of systemic ICI therapy or TT and radiosurgery in 
melanoma patients with BM eligible for both approaches, the majority of these studies 
suggest that a faster and more pronounced or a more durable local response rate as 
well as a reduced distant intracranial failure rate were associated with a time interval 
of less than 4 weeks between initiation of systemic therapy and radiosurgery 58-65. 
However, randomized trials are needed to clarify whether radiosurgery should be 
applicated upfront or delayed at progression. 
 
Does ICI therapy or TT increase the rate of radiation necrosis after radiosurgery 
of brain metastases? 
After radiosurgery, approximately 30% of the lesions increase in size and change their 
pattern of contrast enhancement with a peak at 12-18 months after irradiation 66. Focal 
radiation necrosis is the most important type of late toxicity after radiosurgery. 
Histologically, radiation necrosis is characterized by a central area of necrosis 
surrounded by regions of vascular hyalinization, vasculitis, demyelination, macrophage 
and T-cell infiltration, and reactive astrocytosis 67,68. As these tissue changes are 
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clearly involve immunogenic reactions, an interference with immuno-modulatory 
therapy can be expected. In clinical routine, treatment-related changes on MRI are 
frequently used as surrogate marker for radiation necrosis. Usually, the diagnosis is 
based upon serial MR images, although the diagnostic criteria may differ between 
institutions.  
 
Table 1 shows the rate of radiation necrosis in BM patients treated with radiosurgery 
alone in comparison to BM patients treated with radiosurgery combined with TT or ICI 
therapy. These selected studies (2016-2019; Table 1) suggest that an increased risk 
for radiation necrosis cannot be excluded when radiosurgery is applied in combination 
with ICI therapy while the combination of radiosurgery with TT seems to be less prone 
to radiation necrosis. 
 
Pseudoprogression and Radiosurgery in Combination with ICI 
The occurrence of pseudoprogression after radiosurgery in combination with ICI 
therapy has so far not been well recognized. Compared to radiation necrosis, 
pseudoprogression may differ in terms of the time course of development (typically 
earlier) and the tissue reactions involved. A recent study observed that approximately 
20% of the treated BM showed a transient, reversible increase in size 3-6 months after 
combined treatment compared to 5% after radiosurgery alone 24. Rahman et al. 63 
reported that about 50% of melanoma patients concurrently treated with ipilimumab, 
pembrolizumab, or nivolumab and radiosurgery had an earlier tumor progression 
compared to those treated with ICI therapy with more time elapsed since radiosurgery. 
Despite these earlier tumor progressions, the concurrent patients had a better 
intracranial progression-free survival (30% vs. 12% at 12 months). The phenomenon 
of pseudoprogression has also been observed in melanoma BM patients treated with 
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PD-1 antagonists administered less than 6 weeks after radiosurgery 69. These findings 
warrant consideration during follow-up when interpreting conventional MRI.   
 
PET AND ADVANCED MRI AS NEUROIMAGING TOOLS TO OVERCOME 
CHALLENGES OF CONVENTIONAL MRI 
Currently, ICIs and TT are being investigated in clinical trials while already being used 
in clinical practice for patients with BM. While these therapies hold great promise, 
management of patients undergoing these treatments can be complicated due to brain 
imaging findings on standard MRI, e.g., immune-related pseudoprogression caused by 
ICI therapy or equivocal MRI findings related to radiation in combination with TT. Thus, 
ICIs and TT impose specific requirements on neuroimaging which are not met by 
anatomical MRI. Metabolic PET imaging and advanced MR techniques may provide 
helpful objective information to overcome these imaging challenges. An overview is 
presented in Table 2. 
 
PET 
Oncologic PET imaging using [18F]-2-fluoro-2-deoxy-D-glucose (FDG) has evolved 
over the last decades into the paramount clinical PET modality for cancer diagnostics 
70. Increased glucose metabolism as assessed by an increased FDG uptake is 
commonly seen in proliferating tumor cells due to an increased expression of glucose 
transporters and the enzyme hexokinase, which converts FDG to a phosphorylated 
product. However, the physiological high FDG uptake in the normal brain parenchyma 
hinders the delineation of brain tumors 71, and cerebral inflammatory processes may 




Radiolabeled amino acids are of particular interest for brain tumor imaging using PET 
because of their increased uptake in neoplastic tissue but low uptake in normal brain 
parenchyma, resulting in an improved tumor-to-brain contrast 72. A key feature of 
amino acid tracers is their ability to pass the intact blood-brain-barrier which allows the 
depiction of glioma tissue beyond contrast enhancement in MRI 72 and to differentiate 
tumor progression from non-specific, treatment-related changes, especially in patients 
with BM 73. Recently, the RANO group has analyzed the clinical value of amino acid 
PET in the diagnostic evaluation of brain tumors. It strongly recommended the use of 
this imaging technique in addition to conventional MRI especially for the delineation of 
brain tumor extent, treatment response assessment, evaluation of prognosis of newly 
diagnosed brain tumors, and the differentiation of treatment-related changes from 
tumor progression 71,73-76. Within the group of amino acid PET tracers, [11C]-methyl-L-
methionine (MET), 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA), and O-(2-
[18F]-fluoroethyl)-L-tyrosine (FET) are frequently used 72,77,78. In both gliomas and BM, 
increased uptake of MET, FET, and FDOPA is related to amino acid transporters of 
the L type (LAT; subtypes LAT1 and LAT2), which are overexpressed in tumor tissue 
79-82. Thus, the LAT transporter overexpression in BM makes intracranial metastases 
a compelling target for amino acid PET imaging 82. 
 
In patients with BM, a few PET imaging studies have used other tracers than FDG or 
radiolabeled amino acids. For example, the PET tracer 3´-deoxy-3´-[18F]-
fluorothymidine (FLT) is an analog to the nucleoside thymidine, and was developed to 
assess cellular proliferation by tracking the thymidine salvage pathway 83. The few data 
thus far available suggest that in patients with brain tumors including BM, this tracer 




Importantly, in the USA, only FDG is FDA-approved and all other radiotracers are 
typically only available as part of a clinical trial. 
 
Differentiation of Radiation-induced Changes from Brain Metastasis Recurrence  
FDG PET has been studied to differentiate radiation-induced changes from BM 
relapse. Interestingly, the diagnostic performance of FDG PET varied considerably 
(range of sensitivity, 40-95%; range of specificity, 50-100%) 85-90. Most probably, these 
results might be related to a low number of patients and by variations in methodology. 
 
In contrast, FDOPA PET and MET PET have consistently demonstrated higher 
sensitivity and specificity of approximately 80% in differentiating treatment effect from 
BM recurrence 91-94. Another study has reported a high accuracy for differentiating 
radiation-induced changes from BM relapse after radiosurgery using FDOPA PET, out-
performing perfusion MRI parameters 91% to 76% 95.  Similarly, static and dynamic 
FET PET parameters showed a high diagnostic performance with a sensitivity and 
specificity of 80-90% for the differentiation of radiation-induced changes from locally 
recurrent BM 96-98. An illustrative case is presented in Figure 2. Furthermore, the 
diagnostic performance of amino acid PET seems to be superior to both glucose PET 
and perfusion- and diffusion-weighted MR imaging 90,95.  
 
Recent literature highlights the value of radiomics and artificial intelligence in the field 
of Neuro-Oncology 99-101. Radiomics enables the high-throughput extraction of 
quantitative imaging features from MRI as well as PET 102,103. Using FET PET, it has 
been demonstrated that radiomic textural feature analysis helps distinguishing 
treatment-related changes from BM recurrence 104. For this important clinical question, 
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radiomics analysis using the combination of textural features obtained from FET PET 
and contrast-enhanced MRI achieved a high diagnostic specificity (> 90%) 105. 
 
As stated above, pseudoprogression may occur in patients with BM treated with 
(mono-)immunotherapy using checkpoint inhibitors such as antibodies to CTLA-4 (e.g., 
ipilimumab), PD-1 (e.g., pembrolizumab or nivolumab), or PD-L1 (e.g., atezolizumab). 
A small pilot study (n=5 patients) highlighted the potential of FET PET to identify 
pseudoprogression in patients with BM secondary to melanoma treated with the ICI 
ipilimumab 20. In that study, FET PET imaging findings were correlated with the 
patients’ clinical course after ICI therapy initiation. In the case of pseudoprogression, 
FET PET showed in contrast to the progressive MRI only minimal or even no uptake 
and the outcome was favorable (> 6 months). 
 
Assessment of Treatment Response 
In patients (n=5) with melanoma BM (n=22) treated with TT or ICI therapy, a small 
prospective study found in a subset of patients that metabolic responders may show a 
proliferative reduction on FLT PET despite unchanged findings on standard MRI 106. 
Furthermore, FLT PET responders had a survival of more than 12 months after therapy 
initiation. The pilot data suggest that FLT PET also has the potential to detect a 
reduction of proliferative tumor activity despite apparent morphologic progression on 
conventional MRI (i.e., pseudoprogression). 
 
While the value of amino acid PET for the assessment of treatment response in 
gliomas is well established 107, studies on BM are still remain scarce. Single case 
reports suggest that amino acid PET has the potential to add valuable information to 
standard MRI for the assessment of treatment response. Similar to FLT PET, a 
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reduction of metabolic activity in BM patients secondary to melanoma or NSCLC 
treated with TT could be identified by FET PET, whereas findings on standard MRI 
remained unchanged 73,108. 
 
ADVANCED MRI 
While conventional MRI is exceptional in providing detailed anatomical information of 
both the central nervous system and brain tumors, advanced MRI methods offer the 
ability to yield valuable information concerning the tumor biology, especially at the 
functional, physiologic and molecular level. Commonly used advanced MR techniques 
include perfusion-weighted imaging (PWI), MR spectroscopy (MRS), and diffusion-
weighted imaging (DWI). Due to a better scanner resolution, smaller lesions 
(approximately 5 mm in diameter) can be better evaluated by MRI techniques than by 
PET (optimal lesion diameter, 10 mm or more). 
 
Differentiation of Radiation-induced Changes from Brain Metastasis Recurrence 
 
A recent meta-analysis by Chuang and colleagues 109 examined the value of various 
imaging parameters derived from PWI and MRS for the differentiation of recurrent 
tumor from radiation-induced necrosis in brain tumors patients. Of 397 brain tumor 
patients encompassed by 13 studies, 95 patients suffered from BM, and the remaining 
patiens had gliomas. The main finding of that meta-analysis was that MR spectroscopy 
and MR perfusion might increase the accuracy of differentiating recurrent tumor from 
radiation-induced necrosis in patients with gliomas or BM. In particular, the relative 
cerebral blood volume (rCBV) derived from PWI as well as various MRS metabolite 
ratios in contrast-enhancing lesions was significantly different in BM recurrence 




Regarding the diagnostic performance of PWI, the available studies revealed a 
considerable variability of sensitivity and specificity (range of sensitivity, 56-100%; 
range of specificity, 68-100%) and rCBV thresholds (range, 1.52 - 2.14) 89,95,110-113. 
Although PWI separates radiation-induced changes from BM recurrence with a 
relatively good accuracy in individual studies, there is a significant variability in optimal 
reported thresholds and methodology indicate that further studies and standardization 
are warranted. 
 
For MRS, the specificity for the detection of BM recurrence seems to be high (100% 
across all studies), whereas the sensitivity is relatively low (range, 33-50%) 112,114. Of 
note, MRS studies evaluating this clinical question remain comparatively rare and may 
be limited by a small lesion size (i.e., < 2 cm3). 
 
Apparent diffusion coefficients (ADC) obtained from DWI seem to be inferior to amino 
acid PET using MET for distinguishing radiation-induced injury from BM recurrence 
(area under the curve obtained from receiver operating characteristic curve analyses, 
0.60 vs. 0.81) 90. Furthermore, in contrast to the rCBV, ADC values seem not to be of 
value for the detection of treatment-related changes after stereotactic radiotherapy of 
BM 115. 
 
A radiomics-based prediction model based on contrast-enhanced T1 and FLAIR 
images has been used for distinguishing actual tumor progression from radionecrosis 
after stereotactic radiosurgery for BM patients 116. After cross-validation of the model, 
the radiomics analysis revealed a sensitivity and specificity of 65% and 87%, 




Evaluation of Response to Radiotherapy 
For the evaluation of treatment response in patients with BM, a variety of parameters 
obtained from dynamic susceptibility contrast (DSC), dynamic contrast-enhanced 
(DCE), or arterial spin labeling (ASL) perfusion MRI have been evaluated, including 
predominantly the rCBV, the relative cerebral blood flow (rCBF), and Ktrans (which 
reflects the efflux rate of gadolinium contrast from blood plasma into the tissue). 
 
Taunk and co-workers evaluated pre- and post-treatment stereotactic radiosurgery 
effects in 41 NSCLC patients with 53 BM using DCE PWI 117. Already within the first 
12 weeks after radiosurgery, the PWI parameter Ktrans could be used to predict long-
term response (median follow-up, 11 months) in this group of patients to stereotactic 
radiosurgery. Similar findings regarding the parameter Ktrans have been observed in 
previous PWI studies 118,119. 
 
In 25 patients with 28 BM treated with radiosurgery, rCBF alterations after 6 weeks as 
assessed using DSC or ASL allowed the prediction of the treatment effect (median 
follow-up, 6 months) 120. Similarly, Essig et al. found that a decrease of the rCBV at the 
6-week follow-up helped to predict the treatment outcome with a sensitivity of more 
than 90%. In contrast, the pre-therapeutic rCBV was unable to help predict treatment 
outcome 121. 
 
In patients with BM predominantly ADC values obtained from DWI have also been 
evaluated for the evaluation of treatment response, i.e., especially the response to 
radiosurgery. A few studies have suggested that patients with treatment-responsive 
BM the ADC values increased during follow-up after radiosurgery 122-124. Conversely, 
Jakubovic and colleagues evaluated 42 patients with 70 BM and observed - in contrast 
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to the aforementioned studies - that especially lower ADC values already at one week 
and one month identified responders to radiosurgery 125. Regarding the prediction of 
tumor response, Lee found that initial (pretreatment) ADC values of 107 patients with 
144 BM were able to predict response to radiosurgery with a sensitivity and specificity 
of 86% and 73%, respectively 126. 
  
Additionally, more sophisticated imaging postprocessing techniques of DWI such as 
the calculation of the diffusion abnormality probability function or functional diffusion 
maps seem to provide a reliable prediction of BM response to radiotherapy 127,128. 
 
SUMMARY AND OUTLOOK 
Advanced MRI and PET techniques have the great potential to noninvasively 
investigate the molecular, cellular, and structural components of the tumor and its 
microenvironment. In the light of recent treatment options for patients with BM such as 
ICI and TT and their potential side effects as well as ensuing imaging challenges, it is 
of paramount interest to both visualize and quantify metabolic and (patho)physiological 
changes, especially inflammation, before and during treatment.  
 
Currently, significant evidence suggests that imaging parameters especially derived 
from amino acid PET, PWI, DWI, or MRS may provide valuable additional information 
for the differentiation of treatment-induced changes from BM recurrence and the 
evaluation of treatment response. The PET/RANO group has recently published 
various recommendations which imaging modality should be preferred 73: Amino acid 
PET may be more useful than advanced MRI, whereas FDG PET appears to be 
inferior. However, at present direct comparisons of advanced MRI versus PET are 
limited. When using PET for this indication, amino acid tracers should be preferred 
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because present studies consistently show high diagnostic accuracy. Nevertheless, 
only little data is currently available for evaluation of ICI/TT-treated BM patients using 
these advanced imaging techniques. 
 
It is tempting to speculate that a multimodal approach combining parameters derived 
from each of these advanced imaging techniques may improve the diagnostic 
performance. To further improve the diagnostic accuracy and to assess the resulting 
clinical impact, multicenter studies are warranted that also standardize imaging 
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Figure 1: Radiation necrosis and chronic inflammation in a patient with brain 
metastases of a BRAF-mutated malignant melanoma who had been treated with 
whole-brain radiation therapy and concurrently with dabrafenib plus trametinib. 
Twenty-four months later, the contrast-enhanced MRI suggests brain metastasis 
recurrence (left panel), whereas the FET PET shows only an insignificant uptake, 
consistent with treatment-related effects. Neuropathological findings obtained 
following stereotactic biopsy revealed besides signs of radiation necrosis a 
considerable infiltration of intra- and perivascular T-cells (right panel):  
A: Hyaline, eosinophilic necrosis with only single leukocytes and cell detritus. A 
necrotic vessel wall is hyalinized and thickened (arrowhead). H&E staining; original 
magnification x 200. 
B: Adjacent to necrosis, small fragments of vital brain parenchyma harbor activated 
microglial cells (arrowhead) and reactive astrocytes (asterisk). Two blood vessels are 
heavily infiltrated by lymphocytes (arrows). Tumor cells are absent (insert). H&E 
staining; original magnification x 500; insert: immunohistochemistry with monoclonal 
mouse anti-HMB45 (DCS) and slight counterstaining with hemalum; original 
magnification, x200. 
C: Adjacent to the inflamed blood vessels (arrows), foamy CD68+ macrophages are 
in the process of resorption of necrosis (block arrows). In the brain parenchyma, 
microglial cells (arrowheads) and astrocytes (insert, asterisks) are activated. 
Immunohistochemistry with monoclonal mouse anti-CD68 (DCS) and slight 
counterstaining with hemalum; original magnification, x200; insert: 
immunohistochemistry with monoclonal mouse anti-GFAP (BioGenex) and slight 
counterstaining with hemalum; original magnification, x500. 
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D: CD3+ T cells are the major population of intra- and perivascular infiltrates (arrow). 
Both, CD4+ (left insert) and CD8+ (right insert) T cells contribute to the infiltrates. 
Immunohistochemistry with monoclonal rabbit anti-CD3 (DCS) and slight 
counterstaining with hemalum; original magnification, x200; inserts: 
immunohistochemistry with monoclonal mouse anti-CD4 (left, BioGenex) and with 
monoclonal rabbit anti-CD8 (right, DCS), slight counterstaining with hemalum; original 
magnification, x400.  
 
Figure 2: Radiation necrosis in a patient with brain metastases secondary to a breast 
cancer (ductal carcinoma, HER-2 negative, estrogen and progesterone receptor-
positive) (left panel). Five months after external fractionated radiation therapy, 
contrast-enhanced MRI suggests BM relapse (middle panel). In contrast, FET PET 
shows no increased metabolic activity, indicating treatment-related changes. 
Neuropathological findings obtained following stereotactic biopsy were consistent with 
radiation necrosis (right panel):  
A: Epithelial, pleomorphic tumor with increased mitotic activity (arrowheads) in the 
brain parenchyma expressing cytokeratin (CK) 8 (insert) at initial diagnosis. H&E 
staining; original magnification x 200. Insert: immunohistochemistry with monoclonal 
mouse anti-CK8 (BioGenex, Fremont, CA, USA) and slight counterstaining with 
hemalum; original magnification, x100. 
B: Hyaline, eosinophilic necrosis with only single leukocytes. A necrotic vessel wall is 
hyalinized and thickened (insert). Adjacent vital brain parenchyma shows reactive 
alterations with activated microglial cells and reactive astrocytes. H&E staining; original 
magnification x 200; insert: H&E staining; original magnification, x500. 
C: Necrosis is infiltrated by foamy macrophages (arrows). In the brain parenchyma, 
microglial cells (arrowheads) and astrocytes (insert, asterisks) are activated. 
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Immunohistochemistry with monoclonal mouse anti-MHC class I antigen (DCS, 
Hamburg, Germany) and slight counterstaining with hemalum; original magnification x 
200; insert: immunohistochemistry with monoclonal mouse anti-GFAP (BioGenex) and 
slight counterstaining with hemalum; original magnification, x500. 
D: Epithelial tumor cells were absent from necrosis and vital brain parenchyma. 
Immunohistochemistry with monoclonal mouse anti-CK8 (BioGenex) and slight 
counterstaining with hemalum; original magnification, x200. 
 
 
Table 1: Overview of selected studies (2016-2019) evaluating the rate of radiation necrosis in BM patients treated with radiosurgery alone in 
comparison to BM patients treated with radiosurgery in combination with TT or ICI therapy 
 







ICI / TT timing Rate of RN Comment 
Colaco 137 2016 180 R MM 
SRS + CT 
SRS + ICI or 
TT 
ipi, erlo (< / > 6 mo of SRS) 
17% 
38% / 25% 
increased RN risk for SRS + ICI, no 
effect of timing 
Patel 59 2017 54 R MM 
SRS 
SRS + ICI 
ipi within 4 mo of SRS 
21% 
30% 
insignificantly increased RN risk for 
SRS + ICI 
Yusuf 60 2017 51 P, NR MM 
SRS 
SRS + ICI 
ipi, pembro within 3 mo of SRS 
12% 
3% 
no increased RN risk for SRS + ICI 
Kaidar-Person 138 2017 58 R MM 
SRS 
SRS + ICI 
ipi, pembro, nivo 
0% 
28% 
increased RN risk for SRS + ICI 
Kotecha 58 2018 191 R MM 
SRS 
SRS + TT or 
ICI 
vemura, ipi within 4 wks of SRS 
6% 
0% / 2% 
no increased RN risk for SRS + TT or 
ICI 
Diao 67 2018 91 R MM 
SRS 
SRS + ICI 
ipi (< / > 4 wks of SRS) 
3% 
9% / 7% 
insignificantly increased RN risk for 
SRS + ICI 
Rahman 70 2018 74 R MM SRS + ICI 
ipi, pembro, nivo 
(< / > 4 wks of SRS) 
11% / 13% 
timing was not associated with an 
increased risk for RN  
Nardin 68 2018 25 R MM SRS + ICI 
pembro 
(< / > 4 wks of SRS) 
16% overall 
increased risk for RN, no effect of 
timing 
Du Four 139 2018 142 P, NR MM SRT + ICI  pembro before and after SRS 13% overall increased risk for RN 
Pires da Silva 140 2019 135 R MM SRT + ICI ipi concurrent / after SRS 17% 
increased risk for RN, no effect of 
timing 
Kim 141 2017 1650 R various 
SRS 
SRS + TT 
various TT concurrent to SRS 
5% 
9% 
increased RN risk for SRS + TT 
Weingarten 142 2019 57 R various SRS + ICI 
ipi, pembro, nivo, durva, treme 
before, concurrent and after 
SRS 
7% overall increased RN risk for SRS + ICI 
Hubbeling 143 2018 94 R NSCLC 
SRS 
SRS + ICI 




increased RN risk for SRS + ICI 
Kim 61 2019 84 R breast 
SRS 
SRS + TT 
lapa concurrent to SRS 
4% 
1% 
no increased RN risk for SRS + TT 
Parsai 63 2019 126 R breast 
SRS 
SRS + TT 
lapa concurrent to SRS 
6% 
1% 
no increased RN risk for SRS + TT 
Table
atezo = atezolizumab; BM = brain metastases; breast = breast cancer, CT = cytotoxic chemotherapy; durva = durvalumab; erlo = 
erlotinib; ICI = immune checkpoint inhibitor; ipi = ipilimumab; lapa = lapatinib; MM = malignant melanoma; mo = months; nivo = 
nivolumab; NSCLC = non-small cell lung cancer; P, NR = prospective, non-randomized; R = retrospective; RN = radiation necrosis; SRS 




























Table 2: Overview of main results derived from metabolic PET imaging and advanced MR techniques to overcome imaging challenges 
related to radiotherapy, ICI therapy and TT in patients with BM 
 
 



























analysis is of 
value 112,113, 













SP, but low 
SN 120,122 
ADC values 













n.a. n.a. n.a. n.a. n.a. n.a. 
Evaluation of 
response to  
ICI or TT 
n.a. 







































AA = radiolabeled amino acids, i.e., [11C]-methyl-L-methionine (MET), 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA), or O-(2-
[18F]-fluoroethyl)-L-tyrosine (FET); ADC = apparent diffusion coefficient; BM = brain metastases; DWI = diffusion-weighted imaging; 
FDG = [18F]-2-fluoro-2-deoxy-D-glucose; FLT = 3´-deoxy-3´-[18F]-fluorothymidine; ICI = immune checkpoint inhibitor; MRS = MR 
spectroscopy; n.a. = not available; PWI = perfusion-weighted imaging; rCBV = relative cerebral blood volume; SN = sensitivity; SP = 
specificity; TT = targeted therapy 
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